Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Drug Review Europe Regulation

New Filings At The EMA

  • News

Executive Summary

New medicines under evaluation at the European Medicines Agency.

You may also be interested in...



Novel Combined Contraceptive Estelle Among Nine New Filings At EMA

Mithra says its new oral contraceptive could be a major breakthrough in a “space where there hasn’t been any innovation in decades."

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said.

French Regulator At Odds With EMA Over Safety Restrictions For Pseudoephedrine

The product information for all pseudoephedrine-containing medicines in the EU will need to be updated, the European Medicines Agency said today.

Table

View full table

Topics

Tags:
Drug Review Europe Regulation
Latest Headlines

Preterm Birth Patients Sought By US FDA As Meeting On Treatment Development Looms

US Supreme Court Seems Convinced Purdue Bankruptcy Plan Should Go Forward

US FDA’s START Program Might See Expanded Funding If Pilot Meets Speed Goals

Did Product Quality Decline While US FDA Inspectors Were Away?

See All
UsernamePublicRestriction

Register

PS141914

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By